Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01200290 · ClinicalTrials.gov registry record · Phase 2
A Study in Participants With End-Stage Renal Disease
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01200290 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 18 participants.
The verdict
NCT01200290, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this trial is to explore the effect of LY2127399 on those antibodies that are a barrier to kidney transplant. Transplantation is currently the definitive treatment for End-Stage Renal Disease (ESRD), providing prolonged survival and improved quality of life.
Interventions
- DRUG LY2127399
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01200290
The ClinicalTrials.gov registry entry for NCT01200290 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY2127399 is the first listed.
NCT01200290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01200290 about?
NCT01200290 is a clinical study titled "A Study in Participants With End-Stage Renal Disease". The purpose of this trial is to explore the effect of LY2127399 on those antibodies that are a barrier to kidney transplant. Transplantation is currently the definitive treatment for End-Stage Renal Disease (ESRD), providing prolonged survival and improved quality of life.
What is the current status of trial NCT01200290?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2011-04. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01200290?
The interventions under investigation include: LY2127399 (DRUG).
Who is sponsoring clinical trial NCT01200290?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.